Medical Innovation
Posted: Tue Feb 18, 2025 4:10 am
Sino Biopharmaceutical 01177K: The application for the approval of the drug bemosubishizumab injection combined with anlotinib hydrochloride capsules for the treatment of advanced alveolar soft tissue sarcoma was approved
Aimi Vaccine 06660K: Secondgeneration hightiter adsorbed tetanus vaccine obtains clinical trial approval
Aimi Vaccine 06660K: New technology route suspension culture MDCK cell influenza vaccine obtains clinical trial approval
Acquisition and sale
Chinese Estates Holdings 00127K plans to sell UK properties for £162 greece phone number list million
Hong Kong Smart Energy 01083K plans to acquire 55% equity interest in Changzhou Port Energy Investment Smart Energy for RMB 57.1369 million
Equity Incentive
A total of 3.735 million awards were granted by GuichuangtongqiaoB 02190K
Rights issue
Longhui International Holdings 01007K plans to issue up to 21 million shares first and then new shares to raise a net amount of HK$2.42 million
Hongshengchang Resources 01850K plans to conduct a rights issue of "1 for 4" after a "5for1" share consolidation.
Aimi Vaccine 06660K: Secondgeneration hightiter adsorbed tetanus vaccine obtains clinical trial approval
Aimi Vaccine 06660K: New technology route suspension culture MDCK cell influenza vaccine obtains clinical trial approval
Acquisition and sale
Chinese Estates Holdings 00127K plans to sell UK properties for £162 greece phone number list million
Hong Kong Smart Energy 01083K plans to acquire 55% equity interest in Changzhou Port Energy Investment Smart Energy for RMB 57.1369 million
Equity Incentive
A total of 3.735 million awards were granted by GuichuangtongqiaoB 02190K
Rights issue
Longhui International Holdings 01007K plans to issue up to 21 million shares first and then new shares to raise a net amount of HK$2.42 million
Hongshengchang Resources 01850K plans to conduct a rights issue of "1 for 4" after a "5for1" share consolidation.